Novartis and Matchpoint enter inflammatory disease partnership worth $1bn
The companies will focus on inflammatory diseases that have been historically difficult to treat
Read More
Section: Sales
Sanofi to expand respiratory vaccines pipeline with $1.6bn Vicebio acquisition
The deal includes an early-stage combination vaccine candidate for RSV and hMPV
Read More
LEO Pharma gains access to Boehringer’s skin disease drug for €90m upfront
Spevigo is already approved in over 40 countries to treat generalised pustular psoriasis
Read More
AbbVie gains rights to IGI’s phase 1 trispecific engager in deal worth over $1.9bn
ISB 2001 is in early-stage clinical development for relapsed/refractory multiple myeloma
Read More
Merck to expand respiratory disease portfolio with $10bn Verona acquisition
The deal includes a drug approved in the US for chronic obstructive pulmonary disease
Read More